ArQule, Inc. (ARQL) vs. Top 20 Hedge Fund Stocks in 2019
It has been a fantastic year for equity investors as Donald Trump pressured Federal Reserve to reduce interest rates and finalized the first leg of a trade deal with China.
Arqule Inc (ARQL)
Market is closed
News
- 1 - 10
- Next >>
Hedge Funds Are Starting To Cash Out Of ArQule, Inc. (ARQL)
We can judge whether ArQule, Inc. (NASDAQ:ARQL) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas.
Hedge Funds Have Never Been This Bullish On ArQule, Inc. (ARQL)
Is ArQule, Inc. (NASDAQ:ARQL) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research on a given stock.
Hedge Fund and Insider Trading News: Simon Sadler, Ray Dalio, George Soros, Neil Woodford, Warlander Asset Management, ArQule, Inc. (ARQL), Century Communities Inc (CCS), and More
If Blackpool supporters who fought the arduous campaign against Owen Oyston’s toxic ownership ever fantasised about the ideal alternative, they may have imagined a figure not very different to Simon...
Did Hedge Funds Drop The Ball On ArQule, Inc. (ARQL) ?
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much.
ArQule, Inc. (ARQL): Are Hedge Funds Right About This Stock?
Before we spend days researching a stock idea we'd like to take a look at how hedge funds and billionaire investors recently traded that stock. S&P 500 Index ETF (SPY) lost 8.7% through October 26th.
13G Filing: Biotechnology Value Fund LP and Arqule Inc (ARQL)
Arqule Inc (NASDAQ:ARQL): Mark Lampert's Biotechnology Value Fund LP filed an amended 13D.
You can check out Biotechnology Value Fund LP's latest holdings and filings here.
13G Filing: Biotechnology Value Fund L P and Arqule Inc (ARQL)
Arqule Inc (NASDAQ:ARQL): Mark Lampert's Biotechnology Value Fund LP filed an amended 13D.
You can check out Biotechnology Value Fund LP's latest holdings and filings here.
ArQule, Inc. (ARQL)'s Liver Cancer Drug Fails: What's Next?
ArQule, Inc. (NASDAQ:ARQL) took a real hit at the end of last week, as the company announced data from a late stage oncology trial.
How ArQule, Inc. (ARQL) Stacks Up Against Its Peers
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database.
- 1 - 10
- Next >>
Billionaire Hedge Funds
